White Paper

Bispecific Antibodies Unleashed

Source: Curia
Scientists in lab-GettyImages-1441665026

Advances in disease biology have spurred the rapid development of bispecific antibodies (BsAbs), synthetic proteins capable of targeting two distinct epitopes from different antigens. This bispecific functionality holds immense therapeutic potential, extending their applicability to a wide range of therapies. Originally developed for cancer treatment, BsAbs now show promise in imaging, diagnostics, disease prevention, and treatment. Several BsAbs have already gained regulatory approval, with hundreds more in development.

This white paper delves into the predominant formats and mechanisms of action of bispecific antibodies, the most common techniques for their transient production, and the key aspects of their process development. Additionally, we will highlight the advantages of partnering with a CDMO that offers world-class services from discovery to production, ensuring the success of your BsAbs by delivering precise immunotherapy solutions and avoiding costly regulatory mistakes. Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online